Savara (NASDAQ: SVRA) — Perfil da empresa, notícias e dados financeiros
Savara is a biopharmaceutical company focusing on treatments for rare respiratory diseases, including Pulmonary Alveolar Proteinosis.
Savara
Savara (NASDAQ:SVRA) is a biopharmaceutical company engaged in developing and commercializing treatments for rare respiratory diseases. Through its robust pipeline, Savara aims to address unmet medical needs in conditions such as Pulmonary Alveolar Proteinosis (PAP), where the company has made significant strides with its flagship product Molgradex. The company's projects demonstrate a deep scientific understanding and a commitment to innovation in respiratory care, focusing on improving patient outcomes and quality of life. Savara's objective is to become a leader in rare respiratory diseases by advancing its research, expanding its product portfolio, and reaching patients worldwide who suffer from these debilitating conditions.
Resumo
Operações
Produtos e/ou serviços de Savara
- Molgradex: An inhaled formulation of recombinant human GM-CSF for treating autoimmune pulmonary alveolar proteinosis.
- Apulmiq: A nebulized form of ciprofloxacin for treating non-cystic fibrosis bronchiectasis.
- AeroVanc: The first inhaled antibiotic being developed to address methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients.
- Vanconex: Inhaled therapy aimed at combating chronic lung infections.
- Research on Pulmonary Fibrosis: Focused on developing treatments for idiopathic pulmonary fibrosis, a chronic, progressive lung disease.
- Lung Transplant Support Therapies: Developing treatments to improve the outcomes and survival rates of lung transplant recipients.
equipe executiva do Savara
- Matthew PaulsChairman & CEO
- Robert Matthew LutzCOO & CFO
- Yasmine WasfiChief Medical Officer
- Kate McCabeChief Legal Officer
- Megan CarpenterChief People Officer
- Anne EricksonChief Business & Corporate Affairs Officer
- Brian MaurerHead of Clinical Operations
- Charles LaPreeExecutive VP & Head of Global Regulatory Affairs
- Brian RobinsonExecutive Vice President of Global Medical Affairs
- Siddharth J. AdvantExecutive Vice President of Global Technical Operations
Principais indicadores financeiros
Resultados divulgados pela Savara, em USD.
- Cap. de mercado
- 995,9 mi
- Receita (TTM)
- 1 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -123,5 mi | -118,8 mi | |
| 0 | -103,2 mi | -95,9 mi | |
| 0 | -60 mi | -54,7 mi | |
| 0 | -38,8 mi | -38,2 mi |